help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jordan, V. C.
Right arrow Articles by McCague, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jordan, V. C.
Right arrow Articles by McCague, R.

Endocrinology, Vol 122, 1449-1454, Copyright © 1988 by Endocrine Society


ARTICLES

Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro

VC Jordan, R Koch, S Langan and R McCague
Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison 53792.

The estrogenic and antiestrogenic actions of the geometric isomers of tamoxifen and 4-hydroxytamoxifen were determined in a PRL synthesis assay using primary cultures of dispersed immature rat pituitary gland cells. 4-Hydroxytamoxifen was 100 times more potent as an antiestrogen than tamoxifen. The cis isomer of tamoxifen was a weak estrogen, but the cis isomer of 4-hydroxytamoxifen was converted to the trans isomer during the 6-day assay. This made an accurate determination of the properties of cis-(E)4-hydroxytamoxifen impossible. A series of fixed ring derivatives of the compounds were evaluated in the PRL synthesis assay in vitro to determine their estrogenic and antiestrogenic activities. The fixed ring derivatives of tamoxifen, cis-tamoxifen and trans-(Z)4-hydroxytamoxifen all had properties that were the same as those of the original triphenylethylenes. The fixed ring derivative of the cis-(E) isomer of 4-hydroxytamoxifen was a weak competitive antagonist of estrogen action with only very slight estrogenic properties. This contrasted with the other cis isomers of triphenylethylenes. We propose that the hydroxyl group on the molecule may orient the ligand at the binding site of the estrogen receptor to place the alkylaminoethoxy side-chain in a position to produce antiestrogen action.


This article has been cited by other articles:


Home page
J. Cell Sci.Home page
Z. D. Sharp, M. G. Mancini, C. A. Hinojos, F. Dai, V. Berno, A. T. Szafran, K. P. Smith, T. T. Lele, D. E. Ingber, and M. A. Mancini
Estrogen-receptor-{alpha} exchange and chromatin dynamics are ligand- and domain-dependent
J. Cell Sci., October 1, 2006; 119(19): 4101 - 4116.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
R Aguilar, C Bellido, J C Garrido-Gracia, R Alonso, and J E Sanchez-Criado
Estradiol and its membrane-impermeable conjugate estradiol-BSA inhibit tamoxifen-stimulated prolactin secretion in incubated rat pituitaries.
Reproduction, April 1, 2006; 131(4): 763 - 769.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
F. A. Beland, L. P. McDaniel, and M. M. Marques
Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo
Carcinogenesis, March 1, 1999; 20(3): 471 - 477.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
J. I. Macgregor and V. C. Jordan
Basic Guide to the Mechanisms of Antiestrogen Action
Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1988 by The Endocrine Society